Something else that hasn't been mentioned is the significant cost of running trials. Halving the patients will be a massive expenditure not needeed. While highly unlikely to halve the cost, it could potentially save us a quarter or even a third of the original forecast expense as compared to what it would have cost a week ago. I think our q4 books are going to look pretty good.
Something else that hasn't been mentioned is the significant...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
-0.001(1.30%) |
Mkt cap ! $556.3M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.5¢ | $2.780M | 36.36M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 108996 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 254900 | 3 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
-0.001 ( 1.17 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.5¢ | 17617693 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| IMU (ASX) Chart |